Literature DB >> 110744

Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis.

M M Hreshchyshyn, B S Aron, R C Boronow, E W Franklin, H M Shingleton, J A Blessing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 110744     DOI： 10.1016/0360-3016(79)91209-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  25 in total

Review 1.  Chemotherapy for advanced or recurrent carcinoma of the cervix.

Authors:  J D Bloss
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

Review 2.  Concurrent chemotherapy and radiation therapy in primary cancer of the cervix.

Authors:  J M Schilder; F B Stehman
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

3.  Molecular Strategies of Deoxynucleotide Triphosphate Supply Inhibition Used in the Treatment of Gynecologic Malignancies.

Authors:  Charles A Kunos; Tomas Radivoyevitch
Journal:  Gynecol Obstet (Sunnyvale)       Date:  2011-12-10

Review 4.  Current opinion in cervix carcinoma.

Authors:  Silvia Rodríguez Villalba; Carmen Díaz-Caneja Planell; José Manuel Cervera Grau
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

5.  Chemoradiotherapy: the new standard care for invasive cervical cancer.

Authors:  P G Rose
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 6.  Pharmacokinetics and pharmacodynamics of hydroxyurea.

Authors:  P R Gwilt; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

7.  Alcohol Abuse Decreases Pelvic Control and Survival in Cervical Cancer: An Opportunity of Lifestyle Intervention for Outcome Improvement.

Authors:  Jyoti Mayadev; Chin-Shang Li; Jihoon Lim; Richard Valicenti; Edwin A Alvarez
Journal:  Am J Clin Oncol       Date:  2017-10       Impact factor: 2.339

Review 8.  Progress in gynecologic cancer research: the Gynecologic Oncology Group experience.

Authors:  George A Omura
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

9.  Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.

Authors:  Charles A Kunos; Song-mao Chiu; John Pink; Timothy J Kinsella
Journal:  Radiat Res       Date:  2009-12       Impact factor: 2.841

10.  Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.

Authors:  Charles A Kunos; Tomas Radivoyevitch; Steven Waggoner; Robert Debernardo; Kristine Zanotti; Kimberly Resnick; Nancy Fusco; Ramon Adams; Raymond Redline; Peter Faulhaber; Afshin Dowlati
Journal:  Gynecol Oncol       Date:  2013-04-18       Impact factor: 5.482
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.